- nanoparticles are one of the most promising technologies in the fight against cancer.
- Less than 1 % of nanoparticles reach tumors, reducing their effectiveness.
Since Richard Feynman anticipase the future in his classes at Caltech, nothing would be the same in the field of physics. The arrival of the nanotechnology has allowed us to dream with our eyes invisible sensors that detect diseases at an early stage . Another of the great promises of these investigations were tiny drugs in the form of nanoparticles , they had been recognized as the future in the fight against cancer. Specialists in this discipline, as the Mexican Tessy Lopez Goerne had been said that “nanomedicine is the XXI century medicine. ” But all is not gold that glitters.
Less than 1% of nanoparticles reach tumors, reducing the effectiveness in the fight against cancer
a study published in the journal Nature Reviews Materials considerably lowers expectations this promising technology. And the review of scientists from the University of Toronto (Canada) and Beth Israel Deaconess Medical Center (United States) on research published in the last decade clearly shows that the hype created around the nanoparticles and the cancer was overinflated. According to the results, only the 0.7% of the nanoparticles reached solid tumors , which results in very negative consequences for the application of this type of nanotechnology in medicine and, in particular, in the fight against cancer.
the nanoparticles had been described as “small robots” reaching the target malignant cells, in order to transport the antitumor drug and this act with greater efficiency and less effects side. Several works on nanomedicine pointed that could be applied in the fight against breast cancer and colon or against bacterial infections . What few expected, however, is the low efficiency in the arrival of nanoparticles to solid tumors .
the researchers note that” the nanoparticles are designed to alter the biodistribution and pharmacokinetics of small molecules in patients and allow the arrival of higher doses of the drug to the diseased tissue, with the aim of increasing the therapeutic index, reduce systemic toxicity and / or provide better image signals “. However, the study warns about the lack of effectiveness despite major economic investments (more than one billion dollars in the US in the last ten years) . Therefore the same scientists speak of the reputation of “ hype ” surrounding nanomedicine, which has failed to transform the care of cancer patients in the last fifteen years.
Only two therapies based on nanoparticles, such as Abraxane or Doxil , they have been clinically approved. However, these treatments have not demonstrated significant improvements in therapeutic index. The median reduced efficiency of nanotechnology, less than 1% in the case of solid tumors, is behind not achieving the desired clinical objectives and, therefore, the failure of this promising technology. The nanoparticles, which are tiny pellets formed by organic or inorganic materials such as silver and gold, fail to treat cancer because our body eliminates them before, for example, or that the said particles do not fall within the tumors be effective. His work is not only a review of the “fail” unexpectedness of this technology, but also proposes a strategy for the next three decades to improve the results of such research
April 26, 2016
- ← Cinco documentários e um canal no YouTube para aprofundar o acidente de Chernobyl
- CyberConnect2 announces the development of a new video game →